The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Open accessAbstract
BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Similarly, in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) and Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trials, treatment with CETP inhibitors more than doubled HDL-C levels, but did not appear to reduce the risk of ASCVD events beyond”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Evacetrapib, which raises HDL-C levels by 130% and lowers LDL-C by 37%, was studied in the ACCELERATE trial [63], which was terminated due to futility.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“The CETP inhibitors dalcetrapib (in > 30 000 patients with recent ACS [65]) and evacetrapib (in > 12 000 high-risk patients [63]) were investigated in 2012 and 2017, respectively. Neither clinical study was able to show any clinical benefit associated with CETP inhibitors [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Colocalization, which is a statistical approach that quantifies the extent to which two traits share the same underlying causal variant, and thus can be used to infer vertical pleiotropy 83-85 , can be used to test for such bias 86 , but can suffer from issues of lack of power and/or availability of suitable data from relevant tissues.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
In the citing paper
“Confounding by linkage disequilibrium can be assessed through colocalization 84”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Flagged first, then by citations
Research works printed but not linked: 1
- Krishna R, Clin Pharmacol Ther
Cited by
Sorted by citations
Items 201–300 of 1,001
Chen, J., Li, Y., Zhang, Y., Wang, Y., Zhou, Y., Geng, T., Liu, G., Pan, A., & Liao, Y.-F. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155817 · Cited by 52
The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development
Denny, J. C., Driest, S. L. V., Wei, W., & Roden, D. M. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.951 · Cited by 54
High-density lipoproteins (HDL): Novel function and therapeutic applications
Darabi, M., & Kontush, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159058 · Cited by 52
Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature
Stewart, J., Addy, K., Campbell, S., & Wilkinson, P. (2020) · JRSM Cardiovascular Disease · doi:10.1177/2048004020949326 · Cited by 68
Lee, H., Akhmedov, A. T., & Chen, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.993633 · Cited by 51
Hussain, S. M., Robb, C. E., Tonkin, A. M., Lacaze, P. A., Chong, T. T. ‐., Beilin, L. J., Yu, C., Watts, G. F., Ryan, J. L., Ernst, M. E., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100963 · Cited by 50
Nissen, S. E., Pillai, S. G., Nicholls, S. J., Wolski, K., Riesmeyer, J. S., Weerakkody, G. J., Foster, W. M., McErlean, E. S., Li, L., Bhatnagar, P., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0569 · Cited by 50
Judge, C. S., Ruttledge, S., Costello, M. M., Murphy, R., Loughlin, E. A., Alvarez‐Iglesias, A., Ferguson, J. P., Gorey, S., Nolan, A. M., Canavan, M. D., et al. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2019.02.018 · Cited by 49
Magavern, E. F., Kaski, J. C., Turner, R. M., Drexel, H., Janmohamed, A., Scourfield, A., Burrage, D., Floyd, C. N., Adeyeye, E., Tamargo, J. L., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab018 · Cited by 55
Roberts, R., Chang, C. C., & Hadley, T. D. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.09.004 · Cited by 54
Patti, G., Spinoni, E. G., Grisafi, L., Mehran, R., & Mennuni, M. G. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac049 · Cited by 52
Guo, X., & Ma, L. (2022) · Coronary Artery Disease · doi:10.1097/mca.0000000000001198 · Cited by 54
Vaccination against atherosclerosis
Kobiyama, K., Saigusa, R., & Ley, K. F. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.02.008 · Cited by 48
Berman, A. N., & Blankstein, R. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1175-z · Cited by 48
Cao, J., Nomura, S. O., Steffen, B. T., Guan, W., Remaley, A. T., Karger, A. B., Ouyang, P., Michos, E. D., & Tsai, M. Y. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.11.005 · Cited by 48
Helkkula, P., Kiiskinen, T., Havulinna, A. S., Karjalainen, J., Koskinen, S., Salomaa, V., Daly, M. J., Palotie, A., Surakka, I., Ripatti, S., et al. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009501 · Cited by 47
Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition
Kettunen, J., Holmes, M. V., Allara, E., Anufrieva, O., Ohukainen, P., Oliver-Williams, C., Wang, Q., Tillin, T., Hughes, A. D., Kähönen, M., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000572 · Cited by 47
Bonilha, I., Zimetti, F., Zanotti, I., Papotti, B., & Sposito, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112233 · Cited by 48
Nicholls, S. J., Nelson, A. J., Ditmarsch, M., Kastelein, J. J. P., Ballantyne, C. M., Ray, K. K., Návar, A. M., Nissen, S. E., Goldberg, A. C., Brunham, L. R., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.05.002 · Cited by 46
Brunham, L. R., Lonn, E., & Mehta, S. R. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.04.017 · Cited by 54
Oyama, K., Giugliano, R. P., Blazing, M. A., Park, J., Tershakovec, A. M., Sabatine, M. S., Cannon, C. P., & D, E. B. M. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.011 · Cited by 46
Vaccination in Atherosclerosis
Nettersheim, F. S., Vore, L. D., & Winkels, H. (2020) · Cells · doi:10.3390/cells9122560 · Cited by 47
High HDL-Cholesterol Paradox: SCARB1-LAG3-HDL Axis
Rodríguez, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00902-3 · Cited by 47
Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease?
Razavi, A. C., Jain, V., Grandhi, G. R., Patel, P., Karagiannis, A. D., Patel, N. H., Dhindsa, D. S., Liu, C., Desai, S., Almuwaqqat, Z., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad406 · Cited by 47
Karalis, I. K., & Jukema, J. W. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1004-9 · Cited by 43
Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?
Ruscica, M., Ferri, N., Macchi, C., Corsini, A., & Sirtori, C. R. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1498118 · Cited by 43
The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis
Dangas, K., Navar, A.-M., & Kastelein, J. J. P. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac025 · Cited by 44
Association between abnormal lipid metabolism and tumor
Li, C., Wang, F., Cui, L., Li, S., Zhao, J., & Liao, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1134154 · Cited by 42
Lu, J., Han, G., Liu, X., Chen, B., Peng, K., Shi, Y., Zhang, M., Yang, Y., Cui, J., Song, L., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100874 · Cited by 42
Poliakova, T., & Wellington, C. L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00671-y · Cited by 42
Lorkowski, S. W., Brubaker, G., Rotroff, D. M., Kashyap, S. R., Bhatt, D. L., Nissen, S. E., Schauer, P. R., Aminian, A., & Smith, J. D. (2020) · Biomolecules · doi:10.3390/biom10040551 · Cited by 45
The HDL lipidome is widely remodeled by fast food versus Mediterranean diet in 4 days
Zhu, C., Sawrey-Kubicek, L., Beals, E., Hughes, R. L., Rhodes, C. H., Sacchi, R., & Zivkovic, A. M. (2019) · Metabolomics · doi:10.1007/s11306-019-1579-1 · Cited by 40
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial
Tardif, J., Pfeffer, M. A., Kouz, S., Köenig, W., Maggioni, A. P., McMurray, J. J. V., Mooser, V., Waters, D. D., Grégoire, J. C., L’Allier, P. L., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac374 · Cited by 40
Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Zhuang, T., Wang, S., Yu, X., He, X., Guo, H., & Ou, C. (2024) · Biomarker Research · doi:10.1186/s40364-024-00639-0 · Cited by 41
Genga, K. R., Trinder, M., Kong, H. J., Li, X., Leung, A. K. K., Shimada, T., Walley, K. R., Russell, J. A., Francis, G. A., Brunham, L. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35261-2 · Cited by 40
A Novel Role for CETP as Immunological Gatekeeper: Raising HDL to Cure Sepsis?
Blauw, L. L., Wang, Y., van Dijk, K. W., & Rensen, P. C. N. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.01.003 · Cited by 40
HDL cholesterol levels and susceptibility to COVID-19
Chidambaram, V., Kumar, A., Majella, M. G., Seth, B., Sivakumar, R. K., Voruganti, D. C., Bavineni, M., Baghal, A., Gates, K., Kumari, A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104166 · Cited by 40
Hu, C., Huang, C., Li, J., Liu, F., Huang, K., Liu, Z., Yang, X., Liu, X., Cao, J., Chen, S., et al. (2022) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac159 · Cited by 39
Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management
Agnello, F., Ingala, S., Laterra, G., Scalia, L., & Barbanti, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051251 · Cited by 39
Rabbit models of human diseases for diagnostics and therapeutics development
Mage, R. G., Esteves, P. J., & Rader, C. M. (2018) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2018.10.003 · Cited by 43
Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome
Hackett, G. I. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2018.12.004 · Cited by 39
Apolipoprotein A-I Protects Against Pregnancy-Induced Insulin Resistance in Rats
Wu, B. J., Sun, Y., Ong, K. L., Li, Y., Tang, S., Barter, P. J., & Rye, K. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312282 · Cited by 39
Mørland, J. G., Magnus, P. M., Vollset, S. E., Leon, D. A., Selmer, R. M., & Tverdal, A. (2023) · International Journal of Epidemiology · doi:10.1093/ije/dyad011 · Cited by 40
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients
Nicholls, S. J., Nelson, A. J., Ray, K. K., Ballantyne, C. M., Ditmarsch, M., Kling, D. F., Hsieh, A., Szarek, M. J., Kastelein, J. J. P., & Davidson, M. H. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.056 · Cited by 39
Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile
Blauw, L. L., Noordam, R., Soidinsalo, S., Blauw, C. A., Li‐Gao, R., de Mutsert, R., Berbée, J. F. P., Wang, Y., van Heemst, D., Rosendaal, F. R., et al. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0301-5 · Cited by 38
Zhou, M., Learned, R. M., Rossi, S. J., Tian, H., DePaoli, A. M., & Ling, L. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m089961 · Cited by 39
Yamashita, S., Arai, H., Bujo, H., Masuda, D., Ohama, T., Ishibashi, T., Yanagi, K., Doi, Y., Nakagawa, S., Yamashiro, K., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.55327 · Cited by 40
The mechanistic pathways of oxidative stress in aortic stenosis and clinical implications
Phua, K., Chew, N., Kong, W. K. F., Tan, R., Ye, L., & Poh, K. K. (2022) · Theranostics · doi:10.7150/thno.71813 · Cited by 41
Structure-based mechanism and inhibition of cholesteryl ester transfer protein
Han, X. M., Zhang, M., Liu, J., Wang, J., & Ren, G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01087-1 · Cited by 37
Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition)
Xiao, Y., Yu, B., Chen, C., Wang, S., Hu, D., Wu, C., Luo, Y., Xie, L., Li, C., Peng, D., et al. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2024-0014 · Cited by 37
Cholesteryl ester transfer protein: An enigmatic pharmacology – Antagonists and agonists
Yamashita, S., Ruscica, M., Macchi, C., Corsini, A., Matsuzawa, Y., & Sirtori, C. R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.035 · Cited by 37
Huang, Z.-X., Lin, X., Lu, H., Liang, X., Fan, L., & Liu, X. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09249-5 · Cited by 37
Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor
Zagelbaum, N. K., Yandrapalli, S., Nabors, C. C., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000218 · Cited by 37
Lipid efflux mechanisms, relation to disease and potential therapeutic aspects
Castaño, D., Rattanasopa, C., Monteiro-Cardoso, V. F., Corlianò, M., Liu, Y., Zhong, A., Rusu, M., Liehn, E. A., & Singaraja, R. R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.013 · Cited by 37
Kim, K. A., Kim, N. J., & Choo, E. H. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad331 · Cited by 36
Obicetrapib—the Rebirth of CETP Inhibitors?
Chang, B. J., Laffin, L. J., Sarraju, A., & Nissen, S. E. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01231-5 · Cited by 36
Rautureau, Y., Deschambault, V., Higgins, M., Rivas, D., Mecteau, M., Geoffroy, P., Miquel, G., Uy, K., Sánchez, R., Lavoie, V., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.031134 · Cited by 36
Dyslipidemias in clinical practice
Cabezas, M. C., Burggraaf, B., & Klop, B. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.09.010 · Cited by 36
Zhu, L., Luu, T. N., Emfinger, C. H., Parks, B. A., Shi, J., Trefts, E., Zeng, F., Kuklenyik, Z., Harris, R. C., Wasserman, D. H., et al. (2018) · Diabetes · doi:10.2337/db18-0474 · Cited by 36
Impact of ADCY9 Genotype on Response to Anacetrapib
Hopewell, J. C., Ibrahim, M. A.-H., Hill, M., Shaw, P. M., D, E. B. M., Blaustein, R. O., Bowman, L. J., Landray, M., Sabatine, M. S., Collins, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041546 · Cited by 36
Huang, J., Wang, D., Huang, L., & Huang, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030739 · Cited by 37
Lowering low-density lipoprotein cholesterol: from mechanisms to therapies
Luo, J., Wang, J.-K., & Song, B. (2022) · Life Metabolism · doi:10.1093/lifemeta/loac004 · Cited by 37
Impaired Vascular Redox Signaling in the Vascular Complications of Obesity and Diabetes Mellitus
Akoumianakis, I., & Antoniades, C. A. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7421 · Cited by 37
Translating Evidence of HDL and Plaque Regression
Bartolo, B. A. D., Psaltis, P. J., Bursill, C. A., & Nicholls, S. J. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.307026 · Cited by 38
Korneva, V., Kuznetsova, T. Y., & Julius, U. (2021) · Biomedicines · doi:10.3390/biomedicines9091271 · Cited by 35
Durlach, V., Bonnefont‐Rousselot, D., Boccara, F., Varret, M., Filippo, M. D., Cariou, B., Valéro, R., Charrière, S., Farnier, M., Morange, P., et al. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.10.009 · Cited by 37
Boulanger, M., Li, L., Lyons, S., Lovett, N. G., Kubiak, M. M., Silver, L. E., Touzé, E., Rothwell, P. M., & Study, O. B. O. T. O. V. (2019) · Stroke · doi:10.1161/strokeaha.119.025831 · Cited by 36
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Rossi, M., Fabris, E., Barbisan, D., Massa, L., & Sinagra, G. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00497-3 · Cited by 35
From lipid locus to drug target through human genomics
van der Laan, S. W., Harshfield, E. L., Hemerich, D., Stacey, D., Wood, A., & Asselbergs, F. W. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy120 · Cited by 33
Zaid, M., Miura, K., Okayama, A., Nakagawa, H., Sakata, K., Saitoh, S., Okuda, N., Yoshita, K., Choudhury, S. R., Rodríguez, B. L., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0341 · Cited by 34
Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
Roberts, R. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.08.001 · Cited by 31
Okada, T., Ohama, T., Takafuji, K., Kanno, K., Matsuda, H., Sairyo, M., Zhu, Y., Saga, A., Kobayashi, T., Masuda, D., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.01.002 · Cited by 33
Recent advances in synthetic pharmacotherapies for dyslipidaemias
Sirtori, C. R., Yamashita, S., Greco, M. F., Corsini, A., Watts, G. F., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319845314 · Cited by 34
Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease
Gencer, B., & Mach, F. (2020) · Drugs · doi:10.1007/s40265-019-01243-5 · Cited by 35
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
Schwartz, G. G., Leiter, L. A., Ballantyne, C. M., Barter, P. J., Black, D. M., Kallend, D. G., Laghrissi‐Thode, F., Leitersdorf, E., McMurray, J. J. V., Nicholls, S. J., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2204 · Cited by 34
Targeting HDL in tumor microenvironment: New hope for cancer therapy
Zhao, T., Zhu, N., Shi, Y., Wang, Y., Zhang, C., Deng, C., Liao, D., & Li, Q. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30412 · Cited by 36
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future
Kalaycı, A., Gibson, C. M., Ridker, P. M., Wright, S. D., Kingwell, B. A., Korjian, S., Chi, G., Lee, J., Tricoci, P., Kazmi, S. H. A., et al. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01025-7 · Cited by 35
Residual risks and evolving atherosclerotic plaques
Noothi, S. K., Ahmed, M. R., & Agrawal, D. K. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04689-0 · Cited by 37
Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
Kosmas, C. E., Bousvarou, M. D., Papakonstantinou, E. J., Tsamoulis, D., Koulopoulos, A., Uceta, R. E., Guzman, E., & Rallidis, L. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713622 · Cited by 36
Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22013 · Cited by 37
Larsen, L. E., Stoekenbroek, R. M., Kastelein, J. J. P., & Holleboom, A. G. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312028 · Cited by 34
Cardiovascular risk reduction with icosapent ethyl
Patel, P. N., Patel, S. M., & Bhatt, D. L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000678 · Cited by 33
Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate
Kostner, K., Kostner, G. M., & Wierzbicki, A. S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.04.032 · Cited by 33
Different Approaches in Therapy Aiming to Stabilize an Unstable Atherosclerotic Plaque
Kowara, M., & Cudnoch‐Jędrzejewska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094354 · Cited by 33
Lipoprotein (a): When to Measure and How to Treat?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00951-2 · Cited by 32
Darabi, M., Lhomme, M., Dahik, V. D., Guillas, I., Frisdal, É., Tubeuf, E., Poupel, L., Patel, M., Gautier, E. L., Huby, T., et al. (2022) · The FASEB Journal · doi:10.1096/fj.201800810r · Cited by 35
Variations in time to benefit among clinical trials of cholesterol-lowering drugs
Barter, P. J., & Waters, D. D. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.04.006 · Cited by 33
Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2023) · Critical Care · doi:10.1186/s13054-023-04589-1 · Cited by 30
Bandyopadhyay, D., Ashish, K., Hajra, A., Qureshi, A., & Ghosh, R. K. (2018) · Journal of Lipids · doi:10.1155/2018/3179201 · Cited by 32
Cahill, L. E., Sacks, F. M., Rimm, E. B., & Jensen, M. K. (2019) · Journal of Lipid Research · doi:10.1194/jlr.p093823 · Cited by 33
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects
Ronsein, G. E., Vaisar, T., Davidson, W. S., Bornfeldt, K., Probstfield, J. L., O’Brien, K. D., Zhao, X.-Q., & Heinecke, J. W. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316278 · Cited by 32
HDL maturation and remodelling
Ong, K. L., Cochran, B. J., Manandhar, B., Thomas, S. R., & Rye, K. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159119 · Cited by 35
Lui, J. N. M., Williams, C., Keng, M. J., Hopewell, J. C., Sammons, E. L., Chen, F., Gray, A. M., Bowman, L. J., Landray, S. M. J., Mihaylova, B., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030766 · Cited by 31
Self-citationMorvaridzadeh, M., Zoubdane, N., Heshmati, J., Alami, M., Berrougui, H., & Khalil, A. (2024) · Nutrients · doi:10.3390/nu16050653 · Cited by 39
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction
Wiviott, S. D., Giugliano, R. P., Morrow, D. A., Ferrari, G. M. D., Lewis, B. S., Huber, K., Kuder, J., Murphy, S. A., Forni, D. M., Kurtz, C. E., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0764 · Cited by 31
Multitrait GWAS to connect disease variants and biological mechanisms
Julienne, H., Laville, V., McCaw, Z. R., He, Z., Guillemot, V., Lasry, C., Ziyatdinov, A., Nerin, C., Vaysse, A., Lechat, P., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009713 · Cited by 35
Gordillo‐Marañón, M., Zwierzyna, M., Charoen, P., Drenos, F., Chopade, S., Shah, T., Engmann, J., Casas, J. P., Chaturvedi, N., Papacosta, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25731-z · Cited by 32
Biology, pathophysiology and current therapies that affect lipoprotein (a) levels
Rawther, T., & Tabet, F. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.04.005 · Cited by 31
Jonas, K., & Kopeć, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143514 · Cited by 31
Metadata
- Authors
- The HPS3/TIMI55–REVEAL Collaborative Group
- Affiliations
- University of Oxford (GB)
- Corresponding author
- The HPS3/TIMI55–REVEAL Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-09-28
- Volume
- 377
- Issue
- 13
- Pages
- 1217-1227
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2762777606
- Cited by
- 1,047
- References
- 28
- Citations by year
- 2026: 72 · 2025: 78 · 2024: 99 · 2023: 92 · 2022: 93 · 2021: 118 · 2020: 107 · 2019: 134 · 2018: 195 · 2017: 54
- FWCI
- 137.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10139, NF-SI-0508-10299, RC-PG-0407-10054)
- British Heart Foundation (FS/14/55/30806)
- Versus Arthritis (20639, 18475)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- anacetrapib, cholesteryl ester transfer protein inhibition, atherosclerosis, coronary events, myocardial infarction, coronary revascularization, coronary death, HDL cholesterol, non-HDL cholesterol, LDL cholesterol, atorvastatin, statin therapy, cardiovascular risk reduction, serious adverse events, cancer risk, drug safety, subgroup analysis
- MeSH terms
- Aged, Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Oxazolidinones, Atherosclerosis, Kaplan-Meier Estimate, Cholesterol Ester Transfer Proteins, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
